These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 18172070

  • 1. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA, Van der Velden PA.
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
    [Abstract] [Full Text] [Related]

  • 2. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D, Salvi S, Liénard D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC.
    Cancer Res; 2003 Sep 15; 63(18):5712-5. PubMed ID: 14522889
    [Abstract] [Full Text] [Related]

  • 3. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 15; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 4. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.
    Hum Pathol; 2005 May 15; 36(5):486-93. PubMed ID: 15948115
    [Abstract] [Full Text] [Related]

  • 5. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
    Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, Pavey S, van der Velden P, Out C, Jager MJ, Hayward NK, Gruis NA.
    Br J Cancer; 2005 Jun 06; 92(11):2032-8. PubMed ID: 15928660
    [Abstract] [Full Text] [Related]

  • 6. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC, Kelsell DP, Hungerford JL, Cree IA.
    Invest Ophthalmol Vis Sci; 2002 Sep 06; 43(9):2845-51. PubMed ID: 12202501
    [Abstract] [Full Text] [Related]

  • 7. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2010 Jan 06; 51(1):421-9. PubMed ID: 19661225
    [Abstract] [Full Text] [Related]

  • 8. BRAF mutations in conjunctival melanoma.
    Gear H, Williams H, Kemp EG, Roberts F.
    Invest Ophthalmol Vis Sci; 2004 Aug 06; 45(8):2484-8. PubMed ID: 15277467
    [Abstract] [Full Text] [Related]

  • 9. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma.
    Maat W, Beiboer SH, Jager MJ, Luyten GP, Gruis NA, van der Velden PA.
    Invest Ophthalmol Vis Sci; 2008 Apr 06; 49(4):1291-8. PubMed ID: 18385040
    [Abstract] [Full Text] [Related]

  • 10. The T1799A point mutation is present in posterior uveal melanoma.
    Janssen CS, Sibbett R, Henriquez FL, McKay IC, Kemp EG, Roberts F.
    Br J Cancer; 2008 Nov 18; 99(10):1673-7. PubMed ID: 18985043
    [Abstract] [Full Text] [Related]

  • 11. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
    Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, Hartmann A, Stoehr R.
    Eur Urol; 2006 Nov 18; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
    [Abstract] [Full Text] [Related]

  • 12. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL.
    Cancer Res; 2003 Sep 15; 63(18):5761-6. PubMed ID: 14522897
    [Abstract] [Full Text] [Related]

  • 13. Detection of B-RAF and N-RAS mutations in human melanoma.
    Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, Shih W, Gorski DH.
    J Am Coll Surg; 2005 Mar 15; 200(3):362-70. PubMed ID: 15737846
    [Abstract] [Full Text] [Related]

  • 14. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
    Deichmann M, Thome M, Benner A, Näher H.
    Oncology; 2004 Mar 15; 66(5):411-9. PubMed ID: 15331929
    [Abstract] [Full Text] [Related]

  • 15. The T1799A BRAF mutation is present in iris melanoma.
    Henriquez F, Janssen C, Kemp EG, Roberts F.
    Invest Ophthalmol Vis Sci; 2007 Nov 15; 48(11):4897-900. PubMed ID: 17962436
    [Abstract] [Full Text] [Related]

  • 16. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
    Indsto JO, Kumar S, Wang L, Crotty KA, Arbuckle SM, Mann GJ.
    J Cutan Pathol; 2007 Jun 15; 34(6):448-55. PubMed ID: 17518771
    [Abstract] [Full Text] [Related]

  • 17. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
    Bloethner S, Chen B, Hemminki K, Müller-Berghaus J, Ugurel S, Schadendorf D, Kumar R.
    Carcinogenesis; 2005 Jul 15; 26(7):1224-32. PubMed ID: 15760917
    [Abstract] [Full Text] [Related]

  • 18. Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
    Cui Y, Borysova MK, Johnson JO, Guadagno TM.
    Cancer Res; 2010 Jan 15; 70(2):675-84. PubMed ID: 20068179
    [Abstract] [Full Text] [Related]

  • 19. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP.
    Cancer Res; 2005 Mar 15; 65(6):2412-21. PubMed ID: 15781657
    [Abstract] [Full Text] [Related]

  • 20. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA, DeNicola GM, Winter SP, Tuveson DA.
    Mol Cell; 2009 Nov 13; 36(3):477-86. PubMed ID: 19917255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.